Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2015

English | Dutch
  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos Group
    • Letter from the management
    • At a glance
    • Strategy
    • Going concern statement
    • Risk management
    • The Galapagos share
    • Subsequent events
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • The Galapagos pipeline
    • Target discovery platform
    • Rheumatoid arthritis
      • RA and limitations of current treatments
      • The potential of JAK inhibitors
      • Galapagos’ clinical program for filgotinib for RA
      • Previous clinical trials for filgotinib for RA
      • Jef’s story
    • Inflammatory bowel disease
      • CD and limitations of current treatments
      • The potential of JAK inhibitors for the treatment of CD
      • Clinical program for filgotinib for CD
    • Cystic fibrosis
      • The potential of CFTR modulators for the treatment of CF
      • Novel modulator combinations for treating CF
      • Nikki’s story
      • Katja’s story
    • Idiopathic pulmonary fibrosis
    • Osteoarthritis
  • Risk factors
    • Financial position and need for additional capital
    • Product development, regulatory approval and commercialization
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • Corporate governance
    • Policies
    • Board of Directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Determination of remuneration
      • Remuneration policy
      • Non-executive Directors
      • Executive Directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other Executive Committee members
      • Shares, warrants or other rights
      • Severance payments
      • Severance payments in 2015
      • Claw-back right
    • Conflict of interests and related parties
    • Statement by the Board of Directors
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Significant accounting policies
        • 3. Critical accounting estimates and judgments
        • 4. Segment information
        • 5. Total revenues and other income
        • 6. Operating costs
        • 7. Staff costs
        • 8. Fair value remeasurement of share subscription agreement
        • 9. Other financial income/expenses
        • 10. Taxes
      • Notes 11-20
        • 11. Discontinued operations
        • 12. Result per share
        • 13. Intangible assets
        • 14. Property, plant and equipment
        • 15. Research and Development incentives receivables
        • 16. Restricted cash
        • 17. Trade and other receivables and other current assets
        • 18. Cash and cash equivalents
        • 19. Share capital
        • 20. Other reserves
      • Notes 21-30
        • 21. Translation differences
        • 22. Deferred tax
        • 23. Finance lease liabilities
        • 24. Trade and other liabilities
        • 25. Provisions
        • 26. Operating lease obligations
        • 27. Off-balance sheet arrangements
        • 28. Contingent assets and liabilities
        • 29. Retirement benefit plans
        • 30. Warrant plans
      • Notes 31-36
        • 31. Related parties
        • 32. Consolidated companies as of December 31, 2015
        • 33. Company acquistions and disposals
        • 34. Financial risk management
        • 35. Auditor’s remuneration
        • 36. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor

Financial statements

  • Consolidated financial statements
  • Notes to the consolidated financial statements
    • Notes 1-10
      • 1. General information
      • 2. Significant accounting policies
      • 3. Critical accounting estimates and judgments
      • 4. Segment information
      • 5. Total revenues and other income
      • 6. Operating costs
      • 7. Staff costs
      • 8. Fair value remeasurement of share subscription agreement
      • 9. Other financial income/expenses
      • 10. Taxes
    • Notes 11-20
    • Notes 21-30
    • Notes 31-36
  • Non-consolidated financial statements

You are here:

  • Home
  • Financial statementsNotes to the consolidated financial statements
  • Notes 1-10
  • Notes 1-10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Notes 1-10

Notes 1-10

  • 1. General information
  • 2. Significant accounting policies
  • 3. Critical accounting estimates and judgments
  • 4. Segment information
  • 5. Total revenues and other income
  • 6. Operating costs
  • 7. Staff costs
  • 8. Fair value re-measurement of share subscription agreement
  • 9. Other financial income/expenses
  • 10. Taxes
previous pagenext page
Download Center
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 25 March 2016

Galapagos Annual Report 2015 (PDF)

Download the entire report as PDF.

Download PDF (2.6 MB)
English | Dutch
  • © Copyright 2015 Galapagos NV
  • Colophon
  • Contact
  • Sitemap
© Copyright 2015 Galapagos NV
nexxar - digital reporting evolved - Online Report